Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

13 evidence topics · 10 sources

Summary: heterogeneity evidence for inaxaplin

The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.